Your session is about to expire
← Back to Search
Phosphodiesterase 4 (PDE4) inhibitor
Apremilast for Cutaneous Lichen Planus
Phase 2
Waitlist Available
Led By David M Pariser, MD
Research Sponsored by Virginia Clinical Research, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group
Summary
This trial tests if taking an Apremilast pill regularly for a few months can improve moderate to severe lichen planus, a skin condition that doesn't respond well to other treatments. The pill works by reducing inflammation in the body. Apremilast has shown promise in treating various inflammatory conditions, including psoriasis and lichen planus.
Eligible Conditions
- Cutaneous Lichen Planus
- Lichen Planus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ApremilastExperimental Treatment1 Intervention
Apremilast 20 mg PO administered BID over 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetazolamide
FDA approved
Find a Location
Who is running the clinical trial?
Virginia Clinical Research, Inc.Lead Sponsor
4 Previous Clinical Trials
154 Total Patients Enrolled
Celgene CorporationIndustry Sponsor
445 Previous Clinical Trials
58,636 Total Patients Enrolled
Clare E Foss, MDStudy ChairEastern Virginia Medical School
Share this study with friends
Copy Link
Messenger